|Awarded On||August 20, 2014|
|Title||Biology and Therapy of Basal Bladder Cancers|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Colin Dinney|
Muscle-invasive bladder cancer is a deadly disease. Although approximately half of patients can be cured with surgery and chemotherapy, the other half experiences rapid tumor progression and uniform mortality, usually within 18 months. Essentially no clinical progress has been made in the treatment of muscle-invasive bladder cancer in over three decades. We attribute this lack of progress to a poor understanding of disease biology. Progress in bladder cancer research has been severely hampered by extremely poor levels of research funding. Fortunately, two large projects were completed over the last year that we think will dramatically change this dismal situation. First, The Cancer Genome At...